Key Takeaways
- Phase 2 study of BL1107 (Bausch + Lomb) did not meet its primary endpoint in patients with glaucoma.
- Company will continue pursuing a sustained-release implant for the treatment of geographic atrophy in collaboration with Ripple Therapeutics.
Bausch + Lomb announced topline results from a phase 2 study evaluating BL1107 in 159 adults with primary open-angle glaucoma or ocular hypertension. The study did not meet its primary endpoint and failed to meet key secondary endpoints, leading the company to discontinue the program for this indication.
The drug candidate, acquired from Whitecap Biosciences in 2025, failed to show a change from baseline in visual field mean deviation after 28 days of topical administration, despite promising findings from a smaller phase 1/2a study. BL1107 also failed to achieve secondary endpoint such as low-luminance BCVA responder rates. However, the drug showed a reduction in IOP at day 28, and safety was consistent with prior clinical experience and no new safety signals identified.
Bausch + Lomb acquired BL1107 (formerly known as WB007) primarily for the promise of developing a sustained-release implant for the treatment of geographic atrophy (GA). Given these phase 2 results in patients with glaucoma, the company will now focus on developing the small-molecule sustained-release implant for GA, with trials expected to begin in 2028. Bausch + Lomb will continue collaborating with Ripple Therapeutics, whose patented technology platform is based on a discovery that drugs can be chemically engineered into controlled-release pharmaceuticals without the use of polymers.
